The Food and Drug Administration on April 30 approved an expanded use for Auvelity, dextromethorphan hydrobromide and bupropion hydrochloride extended-release tablets, to treat agitation associated with dementia due to Alzheimer's disease in adults. The agency's notice describes it as the first approved treatment for that condition that is not an antipsychotic. The approval went to Axsome Therapeutics, which developed the tablet under breakthrough therapy designation and priority review; the same product was approved in 2022 for major depressive disorder. The only other drug approved for this symptom, brexpiprazole, cleared by FDA in May 2023, is an antipsychotic. Axsome told investors on May 4 that its commercial launch in the new indication was on track for June 2026.
The agency says the approval rests on two randomized, placebo-controlled trials. The first ran five weeks (NCT03226522) and measured change from baseline to week five on the Cohen-Mansfield Agitation Inventory, a scale scored from caregiver reports; participants on the drug improved more than those on placebo. Neurology Advisor reported the trial randomized 152 people to the drug and 156 to placebo. The second was a relapse-prevention design: people who had already responded during an open-label period were randomly assigned to stay on the drug or switch to placebo, and those who stayed on it went longer before agitation relapsed. A third five-week trial, ADVANCE-2, in 408 participants, did not reach statistical significance on its primary endpoint, with mean Cohen-Mansfield reductions of 13.8 points on the drug and 12.6 on placebo, according to Axsome's results announcement filed with the Securities and Exchange Commission on December 30, 2024.
The label is unchanged in its central cautions. Auvelity carries a boxed warning about increased risk of suicidal thoughts and behaviors in adolescents and young adults taking antidepressants, and FDA says prescribers should watch for clinical worsening, particularly early in treatment. The medicine can cause seizures, with risk rising as the dose rises, and can raise blood pressure or trigger mania in susceptible patients. Before starting it, FDA says health care providers should assess blood pressure, screen for personal or family history of bipolar disorder, and determine whether the person is already taking anything containing bupropion or dextromethorphan. The prescribing information contraindicates use with monoamine oxidase inhibitors and requires 14 days between an MAOI and this drug in either direction, warns about serotonin syndrome when it is combined with other serotonergic medicines, and lowers the maximum dose when it is taken with strong CYP2D6 inhibitors, a category that includes some antidepressants. The label also states plainly that it is not indicated as an as-needed treatment for agitation: it is a scheduled daily medicine, not something to reach for during an incident.
The indication is narrow. It covers agitation associated with dementia due to Alzheimer's disease, not agitation in vascular dementia, dementia with Lewy bodies or frontotemporal dementia, where the older off-label practice is untouched by this decision. The label's geriatric section records 720 patients aged 65 and over treated with Auvelity in the studies supporting this use, 368 of them aged 65 to under 75 and 352 aged 75 and over. The Alzheimer's Association, which welcomed the approval on the day it was issued, described agitation as among the hardest symptoms to manage for people with the disease and the families supporting them.